Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 67

Sort by

Sort Order Select

Journal Articles

Dual HDAC and EZH2 Inhibition Primes Mosunetuzumab for the Treatment of Germinal Center-Derived B-Cell Lymphoma

Ted B. Piorczynski, Saagar Jain, Manuel Pazos, II, Yun Kyoung Tiger, Seda S. Tolu, Jennifer E. Amengual

Blood (2024) 144 (Supplement 1): 973.

https://doi.org/10.1182/blood-2024-194360

Published: 2024

Journal Articles

S2207: Randomized Phase II Study of the Addition of Targeted Agents to Tafasitamab-Lenalidomide in Transplant Ineligible Patients with Relapsed/Refractory LBCL

Jennifer E. Amengual, Hongli Li, Patrick M. Reagan, Tareq Al Baghdadi, Hayder Saeed, Joseph M Unger, Alexey Danilov, Michael Leblanc, Jonathan W. Friedberg, Sonali M. Smith

Blood (2024) 144 (Supplement 1): 3123.2.

https://doi.org/10.1182/blood-2024-199784

Published: 2024

Journal Articles

Safety and Efficacy in Pediatric Patients with Relapsed/Refractory Classic Hodgkin Lymphoma Enrolled on an Intergroup Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin (E4412)

Christopher J. Forlenza, Opeyemi Jegede, Stephen M. Ansell, Christian Steidl, Yasodha Natkunam, David W. Scott, Neha Mehta-Shah, Jennifer E. Amengual, Peter D. Cole, Brad S. Kahl, Catherine S. Diefenbach

Blood (2024) 144 (Supplement 1): 4427.

https://doi.org/10.1182/blood-2024-201624

Published: 2024

Journal Articles

Combination JAK Inhibition and Immune Checkpoint Blockade for the Treatment of 9p Amplified Lymphomas

Seda S. Tolu, Ted B. Piorczynski, Manuel Pazos, II, Brian Estrella, Hua-Jay J Cherng, Barbara Pro, Jennifer E. Amengual

Blood (2024) 144 (Supplement 1): 336.

https://doi.org/10.1182/blood-2024-203382

Published: 2024

Journal Articles

Improving Outcomes in Plasmablastic Lymphoma: A Multicenter Experience from an American Cohort

Blood (2024) 144 (Supplement 1): 573.

https://doi.org/10.1182/blood-2024-198008

Published: 2024

Journal Articles

Diagnostic Utility of the 18 f-FDG PET/CT Scan in Solid Organ Transplant Patients with EBV Reactivation at Risk for Post-Transplant Lymphoproliferative Disorder

Hua-Jay J Cherng, Rebecca Scalabrino, Patrick Gould, Alexander Sanjurjo, Brian Cuzzo, Saagar Jain, Hong Y Ma, Maegan Ford, Evelyn H. Orlando, Dorine De Jong, Manuela A Orjuela, Andrew H. Lipsky, Seda S. Tolu, Barbara Pro, Jennifer E. Amengual, Kathleen M Capaccione

Blood (2024) 144 (Supplement 1): 3077.

https://doi.org/10.1182/blood-2024-194265

Published: 2024

Journal Articles

Etctn P10500: Phase 1 Study of Tazemetostat Plus Belinostat for the Treatment of Relapsed or Refractory Lymphoma

Jennifer E. Amengual, Aung M. Tun, Ted B. Piorczynski, Yun Kyoung Tiger, Victor Yazbeck, Hua-Jay J Cherng, Seda S. Tolu, Barbara Pro, Diane Durecki, Jan Beumer, Neil Kelleher, Naomi Sender, Sarah Sta Ana, Anxhela Kalia, Beatriz Raposo Corradini, Yu Shyr, Patricia LoRusso, Lorraine Pelosof, Richard Piekarz

Blood (2024) 144 (Supplement 1): 3112.

https://doi.org/10.1182/blood-2024-199650

Published: 2024

Journal Articles

Association between Food Insecurity, Financial Toxicity, and Healthcare Utilization in Patients with Lymphoma

Kishan A Bhatt, David M. DeStephano, Rhea K Khurana, Claire Sathe, Seda S. Tolu, Hua-Jay J. Cherng, Jennifer E. Amengual, Barbara Pro, Dawn L Hershman, Justine M. Kahn, Melissa P Beauchemin

Blood (2024) 144 (Supplement 1): 5042.

https://doi.org/10.1182/blood-2024-210508

Published: 2024

Journal Articles

First-in-Class HAT Activator (YF2) Combined with JAK/STAT Inhibitor (ruxolitinib) Unveils Potential Novel Treatment Approach for HDAC Inhibitor-Resistant CTCL

Manuel Pazos, II, Brian Estrella, Ted B. Piorczynski, Seda S. Tolu, Wenxuan Huang, Yun Kyoung Ryu, Jennifer E Amengual

Blood (2023) 142 (Supplement 1): 4184.

https://doi.org/10.1182/blood-2023-186639

Published: 2023

Journal Articles

The Effect of Preemptive Rituximab Treatment in Patients with EBV Viremia after Solid Organ Transplantation on the Development of Post-Transplant Lymphoproliferative Disorder

Blood (2023) 142 (Supplement 1): 990.

https://doi.org/10.1182/blood-2023-177823

Published: 2023

Journal Articles

JAK1/2 Inhibition Modulates Key Markers of Lymphomagenesis in 9p24.1 Amplified Lymphoma, Priming for Enhanced Antigenicity

Seda S. Tolu, Ted B. Piorczynski, Manuel Pazos, II, Brian Estrella, Wenxuan Huang, Yun Kyoung Ryu, Hua-Jay J. Cherng, Barbara Pro, Jennifer E. Amengual

Blood (2023) 142 (Supplement 1): 6118.

https://doi.org/10.1182/blood-2023-180875

Published: 2023

Journal Articles

Results from an Intergroup Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Classic Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Research Group (E4412)

Catherine S Diefenbach, Opeyemi Jegede, Stephen M Ansell, Christian Steidl, Yasodha Natkunam, David W. Scott, Neha Mehta-Shah, Jennifer E Amengual, Christopher J. Forlenza, Peter D. Cole, Nancy L. Bartlett, Kevin A. David, Ranjana H. Advani, Richard F. Ambinder, Sachdev Thomas, Sami Ibrahimi, Brad S. Kahl

Blood (2023) 142 (Supplement 1): 607.

https://doi.org/10.1182/blood-2023-184531

Published: 2023

Journal Articles

Outcomes of Contemporary Novel Agent and Stem Cell Transplantation in Relapsed/Refractory PTCL

Seda S. Tolu, Caitlin Gribbin, Madhav R Seshadri, Zhengming Chen, Evelyn Orlando, Justin Grenet, Rajbir Toor, Alexander Sanjurjo, Adrienne A. Phillips, Tsiporah B. Shore, Peter Martin, John P. Leonard, Barbara Pro, Jennifer E. Amengual, Jia Ruan

Blood (2023) 142 (Supplement 1): 1698.

https://doi.org/10.1182/blood-2023-178231

Published: 2023

Journal Articles

Outcomes in Minorities with PTCL By Clinical Trial Enrollment

Seda S. Tolu, Alexander Sanjurjo, David Destephano, Barbara Pro, Jennifer E. Amengual

Blood (2023) 142 (Supplement 1): 4431.

https://doi.org/10.1182/blood-2023-177722

Published: 2023

Journal Articles

Methylated Whole Genome Cell-Free DNA Sequencing before Chimeric Antigen Receptor T-Cell Therapy for Large B-Cell Lymphoma Predicts Treatment Outcomes

Hua-Jay J. Cherng, Xiaojing Yang, Ryan Yancey, Christian A Gordillo, Ted B. Piorczynski, Hei T. Chan, Kenneth N. Ofori, Govind Bhagat, Andrea Califano, Barbara Pro, Keith Booher, Jennifer E. Amengual, Ran Reshef, Abu A. I. Sina

Blood (2023) 142 (Supplement 1): 4371.

https://doi.org/10.1182/blood-2023-178376

Published: 2023

Journal Articles

Tazemetostat in Combination with Lenalidomide and Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma: Updated Phase 1b Results of Symphony-1 with 22.5 Months Follow-up

Gilles Salles, Steven I. Park, Tycel J. Phillips, Jennifer E. Amengual, David J Andorsky, Philip Campbell, Pamela McKay, John P. Leonard, Yingxue Chen, Jade Chen, Rajat Bannerji, Apoorva Kapopara, Attila Szanto, Franck Morschhauser

Blood (2023) 142 (Supplement 1): 3035.

https://doi.org/10.1182/blood-2023-179910

Published: 2023

Journal Articles

Combination Epigenetic Therapy Using YF2, a First-in-Class Histone Acetyltransferase Activator, Restores Immunogenicity in Diffuse Large B-Cell Lymphoma

Ted B. Piorczynski, Yun Kyoung Ryu, Manuel Pazos, II, Wenxuan Huang, Seda S. Tolu, Brian Estrella, Jennifer E Amengual

Blood (2023) 142 (Supplement 1): 4391.

https://doi.org/10.1182/blood-2023-179271

Published: 2023

Journal Articles

How I treat posttransplant lymphoproliferative disorder

Jennifer E. Amengual, Barbara Pro

Blood (2023) 142 (17): 1426–1437.

https://doi.org/10.1182/blood.2023020075

Published: 2023

Journal Articles

Queen's gambit: response-adapted win in CAYA with cHL

Seda S. Tolu, Jennifer E. Amengual

Blood (2023) 141 (17): 2037–2038.

https://doi.org/10.1182/blood.2022019339

Published: 2023

Journal Articles

Treatment Modalities Effect on Outcome in Post-Transplant Lymphoproliferative Disorder

Maegan Ford, Evelyn Orlando, Zhezhen Jin, Andrew H. Lipsky, Ahmed Sawas, Barbara Pro, Jennifer E. Amengual

Blood (2022) 140 (Supplement 1): 3794–3795.

https://doi.org/10.1182/blood-2022-163813

Published: 2022

NARROW

Dual HDAC and EZH2 Inhibition Primes Mosunetuzumab for the Treatment of Germinal Center-Derived B-Cell Lymphoma

S2207: Randomized Phase II Study of the Addition of Targeted Agents to Tafasitamab-Lenalidomide in Transplant Ineligible Patients with Relapsed/Refractory LBCL

Safety and Efficacy in Pediatric Patients with Relapsed/Refractory Classic Hodgkin Lymphoma Enrolled on an Intergroup Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin (E4412)

Combination JAK Inhibition and Immune Checkpoint Blockade for the Treatment of 9p Amplified Lymphomas

Improving Outcomes in Plasmablastic Lymphoma: A Multicenter Experience from an American Cohort

Diagnostic Utility of the 18 f-FDG PET/CT Scan in Solid Organ Transplant Patients with EBV Reactivation at Risk for Post-Transplant Lymphoproliferative Disorder

Etctn P10500: Phase 1 Study of Tazemetostat Plus Belinostat for the Treatment of Relapsed or Refractory Lymphoma

Association between Food Insecurity, Financial Toxicity, and Healthcare Utilization in Patients with Lymphoma

First-in-Class HAT Activator (YF2) Combined with JAK/STAT Inhibitor (ruxolitinib) Unveils Potential Novel Treatment Approach for HDAC Inhibitor-Resistant CTCL

The Effect of Preemptive Rituximab Treatment in Patients with EBV Viremia after Solid Organ Transplantation on the Development of Post-Transplant Lymphoproliferative Disorder

JAK1/2 Inhibition Modulates Key Markers of Lymphomagenesis in 9p24.1 Amplified Lymphoma, Priming for Enhanced Antigenicity

Results from an Intergroup Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Classic Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Research Group (E4412)

Outcomes of Contemporary Novel Agent and Stem Cell Transplantation in Relapsed/Refractory PTCL

Outcomes in Minorities with PTCL By Clinical Trial Enrollment

Methylated Whole Genome Cell-Free DNA Sequencing before Chimeric Antigen Receptor T-Cell Therapy for Large B-Cell Lymphoma Predicts Treatment Outcomes

Tazemetostat in Combination with Lenalidomide and Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma: Updated Phase 1b Results of Symphony-1 with 22.5 Months Follow-up

Combination Epigenetic Therapy Using YF2, a First-in-Class Histone Acetyltransferase Activator, Restores Immunogenicity in Diffuse Large B-Cell Lymphoma

How I treat posttransplant lymphoproliferative disorder

Queen's gambit: response-adapted win in CAYA with cHL

Treatment Modalities Effect on Outcome in Post-Transplant Lymphoproliferative Disorder

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only